Niacin In Patients With Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

Effect None
Trial Design Double blind
Trial Length 6+ Months
Number of Subjects 3196
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
The addition of time release niacin (1,500-2,000mg) daily for two years with one year followup alongside statin therapy, compared to statin therapy alone, improved biomarkers of cardiovascular health (LDL, HDL, triglycerides by 12%, 25%, and 28.6% respectively) but failed to reduce the risk of cardiovascular events such as ischemic stroke or myocardial infarction any more than statins alone.

Other biomarkers that were not elaborated on, Apolipoproteins A1 and B as well as lipoprotein(a), did not appear to be significantly influenced; no measurements were taken of these at the end of two years, just after 1 and 3 years (for the apolipoproteins) or after 1 year (lipoprotein(a))
Funding issues for this study:
Study conducted with a Grant from Abbott labratories; Niacin donated from Abbott and Simvastatin from Merck

Full details on all 3 studies are available to Examine Plus members.

Already a member? Login now to access.